bufuralol has been researched along with propranolol in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (50.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; el Tayar, N; Testa, B; Van de Waterbeemd, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Beretta-Piccoli, C; de Châtel, RD; Hirsch, D; Reubi, FC; Weidmann, P; Ziegler, W | 1 |
| Bonelli, J; Kaik, G; Magometschnigg, D; Rameis, H | 1 |
| Lennard, MS | 1 |
| Smith, RL | 1 |
| East, PB; Francis, RJ; Pringle, TH; Shanks, RG | 1 |
| Belz, GG; Matthews, JH; Palm, D; Wellstein, A | 1 |
| Finch, MB; Johnston, GD; Shanks, RG | 1 |
| Lennard, MS; Ramsay, LE; Silas, JH; Tucker, GT; Woods, HF | 1 |
| Balant, LP; Dayer, P; Fabre, J | 1 |
| Cho, AK; Distefano, EW; Fujimoto, M; Jayasinghe, A; Lin, LY; Schmitz, DA | 1 |
| Chow, T; Funae, Y; Hiroi, T; Imaoka, S | 1 |
3 review(s) available for bufuralol and propranolol
| Article | Year |
|---|---|
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Models, Molecular; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1988 |
Oxidation phenotype and the metabolism and action of beta-blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Drug Interactions; Ethanolamines; Humans; Hypertension; Kinetics; Metoprolol; Oxidation-Reduction; Phenotype; Propranolol; Timolol | 1985 |
Consequences of renal insufficiency on the hepatic clearance of some drugs.
Topics: Adrenergic beta-Antagonists; Biotransformation; Dextropropoxyphene; Ethanolamines; Humans; Kidney Diseases; Kidney Failure, Chronic; Kinetics; Liver; Models, Biological; Oxprenolol; Pharmaceutical Preparations; Propanolamines; Propranolol; Renal Dialysis | 1983 |
3 trial(s) available for bufuralol and propranolol
| Article | Year |
|---|---|
[Interrelations between blood pressure, blood volume, plasma renin and urinary catecholamines during beta-blockade in essential hypertension (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzofurans; Blood Pressure; Blood Volume; Body Weight; Catecholamines; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Potassium; Propranolol; Renin | 1976 |
Pharmacodynamic and pharmacokinetic studies on bufuralol in man.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Double-Blind Method; Ethanolamines; Heart Rate; Humans; Kinetics; Male; Physical Exertion; Propranolol; Random Allocation | 1986 |
Peripheral vascular effects of bufuralol in hypertensive and normal subjects: a comparison with propranolol and pindolol.
Topics: Adult; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Ethanolamines; Fingers; Forearm; Heart Rate; Humans; Hypertension; Male; Middle Aged; Pindolol; Propranolol; Regional Blood Flow | 1986 |
14 other study(ies) available for bufuralol and propranolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Hemodynamic changes in hypertensive patients at rest and during physical exercise before and after acute i.v. administration of bufuralol-HCl or propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Benzofurans; Ethanolamines; Hemodynamics; Humans; Hypertension; Middle Aged; Physical Exertion; Propranolol; Rest | 1979 |
Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.
Topics: Adrenergic beta-Antagonists; Animals; Biological Availability; Blood Pressure; Debrisoquin; Ethanolamines; Glucuronates; Humans; Hydroxylation; Kinetics; Lipids; Metoprolol; Phenotype; Polymorphism, Genetic; Propranolol; Solubility; Structure-Activity Relationship; Timolol | 1985 |
In vitro receptor occupancy allows to establish equieffective doses of beta-blockers with different pharmacodynamic profiles in man. Investigations with propranolol and bufuralol.
Topics: Adult; Binding, Competitive; Ethanolamines; Heart Rate; Humans; In Vitro Techniques; Kinetics; Male; Propranolol; Receptors, Adrenergic, beta; Reticulocytes; Stroke Volume; Vascular Resistance | 1985 |
Polymorphic metabolism of beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Biotransformation; Drug Interactions; Ethanolamines; Heart Rate; Humans; Metoprolol; Propranolol | 1984 |
Selective mechanism-based inactivation of rat CYP2D by 4-allyloxymethamphetamine.
Topics: Animals; Cytochrome P-450 Enzyme Inhibitors; Dealkylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanolamines; Female; Male; Methamphetamine; Phencyclidine; Propranolol; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 1996 |
Catalytic specificity of CYP2D isoforms in rat and human.
Topics: Alcohol Oxidoreductases; Animals; Aryl Hydrocarbon Hydroxylases; Catalysis; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Debrisoquin; Ethanolamines; Humans; In Vitro Techniques; Isoenzymes; Magnetic Resonance Spectroscopy; Microsomes, Liver; Mixed Function Oxygenases; Propranolol; Rats; Recombinant Proteins; Substrate Specificity | 2002 |